#ECTRIMS2021 – Early Ocrevus Slows MS Better Versus 2-year Delay

#ECTRIMS2021 – Early Ocrevus Slows MS Better Versus 2-year Delay

309508

#ECTRIMS2021 – Early Ocrevus Slows MS Better Versus 2-year Delay

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Early use of Ocrevus (ocrelizumab) continues to significantly slow disability progression after 7.5 years in people with relapsing multiple sclerosis (MS) and after eight years in those with primary progressive MS (PPMS), according to new analyses…

You must be logged in to read/download the full post.